Durable Response After 2 Doses of Pembrolizumab in a Patient With Non–Small-Cell Lung Cancer With an Isolated Brain Metastasis

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical lung cancer 2019-09, Vol.20 (5), p.e552-e554
Hauptverfasser:	Uprety, Dipesh, Arjyal, Lubina, Vallatharasu, Yazhini, Bista, Amir, Wittchow, Richard J., Marinier, David E.
Format:	Artikel
Sprache:	eng
Schlagworte:	Aged Antibodies, Monoclonal, Humanized - therapeutic use Antineoplastic Agents - therapeutic use Biomarkers, Pharmacological Brain Neoplasms - drug therapy Brain Neoplasms - secondary Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - secondary Durable response Female Humans Immunotherapy Immunotherapy - methods Lung Neoplasms - drug therapy Lung Neoplasms - pathology Neoplasm Staging NSCLC Pembrolizumab Stage IV Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!